HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J8540 | Dexamethasone Oral | Baycadron, ZoDex, Decadron | 0.25 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1983 | Jan 1, 2006 | In Use | ||
NA | Mesna | Mesnex | 400 mg | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Yes | 2002 | In Use | |||
NA | Flutamide | Euflex, Eulexin | 125 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1989 | In Use | ||||
J8670 | Rolapitant | Varubi | 1 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2015 | Jan 1, 2017 | In Use | ||
J7509 | Methylprednisolone Acetate | Medrol, Medrol Acetate, SOLU-medrol, Methylpred DP | 4 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1998 | Jan 1, 2000 | In Use | ||
NA | tretinoin | Vesanoid | 10 mg | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Yes | 1995 | In Use | |||
NA | Dasatinib | Sprycel | 80 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Osimertinib | Tagrisso | 80 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | In Use | |||
NA | Osimertinib | Tagrisso | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | In Use | |||
NA | Ivosidenib | Tibsovo | 250mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2018 | In Use | |||
NA | Estradiol | Estrace | 2 mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
NA | Megestrol Acetate | Megace | 20mg, 40mg | Hormonal Therapy | Progestin | Yes | 1988 | In Use | ||||
NA | Tazemetostat | Tazverik | 200mg | Chemotherapy | Enzyme Inhibitor | EZH2 | Yes | 2020 | In Use | |||
Futibatinib | Lytgobi | 4mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Yes | 2023 | In Use | ||||
NA | Bosutinib | Bosulif | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
NA | Vismodegib | Vismodegib | 150 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2012 | In Use | |||
NA | cobimetinib | Cotellic | 20 mg | Chemotherapy | MAPK/MEK Inhibitor | BRAF | Yes | 2015 | In Use | |||
NA | Niraparib | Zejula | 100 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | Talazoparib | Talzenna | 0.25mg, 1mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2018 | In Use | |||
NA | Purixan | Purixan | 20mg | Chemotherapy | Antimetabolite | Purine | Yes | 2014 | In Use | |||
NA | ixazomib | Ninlaro | 3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
NA | ixazomib | Ninlaro | 4 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
NA | ixazomib | Ninlaro | 2.3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.